These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 36052554)

  • 1. The Hippo pathway and its correlation with acute kidney injury.
    Zhang C; Li CL; Xu KX; Zheng ZH; Cheng GZ; Wu HJ; Liu J
    Zool Res; 2022 Sep; 43(5):897-910. PubMed ID: 36052554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets.
    Habshi T; Shelke V; Kale A; Lech M; Gaikwad AB
    Drug Discov Today; 2023 Aug; 28(8):103649. PubMed ID: 37268185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the Hippo pathway in regeneration and fibrogenesis after ischaemic acute kidney injury: YAP is the key effector.
    Xu J; Li PX; Wu J; Gao YJ; Yin MX; Lin Y; Yang M; Chen DP; Sun HP; Liu ZB; Gu XC; Huang HL; Fu LL; Hu HM; He LL; Wu WQ; Fei ZL; Ji HB; Zhang L; Mei CL
    Clin Sci (Lond); 2016 Mar; 130(5):349-63. PubMed ID: 26574480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo-YAP/MCP-1 mediated tubular maladaptive repair promote inflammation in renal failed recovery after ischemic AKI.
    Zheng Z; Li C; Shao G; Li J; Xu K; Zhao Z; Zhang Z; Liu J; Wu H
    Cell Death Dis; 2021 Jul; 12(8):754. PubMed ID: 34330891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF Receptor-Dependent YAP Activation Is Important for Renal Recovery from AKI.
    Chen J; You H; Li Y; Xu Y; He Q; Harris RC
    J Am Soc Nephrol; 2018 Sep; 29(9):2372-2385. PubMed ID: 30072422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
    Anorga S; Overstreet JM; Falke LL; Tang J; Goldschmeding RG; Higgins PJ; Samarakoon R
    FASEB J; 2018 May; 32(5):2644-2657. PubMed ID: 29298862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippo signaling modulation and its biological implications in urological malignancies.
    Tong T; Huang M; Yan B; Lin B; Yu J; Teng Q; Li P; Pang J
    Mol Aspects Med; 2024 Aug; 98():101280. PubMed ID: 38870717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine.
    Moya IM; Halder G
    Nat Rev Mol Cell Biol; 2019 Apr; 20(4):211-226. PubMed ID: 30546055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo signalling in the liver: role in development, regeneration and disease.
    Russell JO; Camargo FD
    Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):297-312. PubMed ID: 35064256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of the mammalian Hippo signaling pathway.
    Ji XY; Zhong G; Zhao B
    Yi Chuan; 2017 Jul; 39(7):546-567. PubMed ID: 28757470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.
    Johnson R; Halder G
    Nat Rev Drug Discov; 2014 Jan; 13(1):63-79. PubMed ID: 24336504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
    Juan WC; Hong W
    Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo Pathway: An Emerging Regulator of Craniofacial and Dental Development.
    Wang J; Martin JF
    J Dent Res; 2017 Oct; 96(11):1229-1237. PubMed ID: 28700256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo signaling pathway in liver regeneration and tumorigenesis.
    Hong L; Cai Y; Jiang M; Zhou D; Chen L
    Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):46-52. PubMed ID: 25476204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo signalling pathway in bone homeostasis: Under the regulation of mechanics and aging.
    Li Z; Lin J; Wu J; Suo J; Wang Z
    Cell Prolif; 2024 Oct; 57(10):e13652. PubMed ID: 38700015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.